SCHEMBL1279796

SCHEMBL1279796

CC(C)(C)OC(=O)N1CC[C@H]([C@@H](O)CCSc2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.51
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
USP30 Q70CQ3 3/20 0.45
IDO1 P14902 4/20 0.45
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
STS P08842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1279798 1.00 GPR119 (0.51) GPR119JAK2JAK1KDM4EPKM
SCHEMBL1279405 1.00 GPR119 (0.51) GPR119JAK2JAK1KDM4EPKM
SCHEMBL1279402 1.00 GPR119 (0.51) GPR119JAK2JAK1KDM4EPKM
SCHEMBL12469109 0.85 ALDH1A1 (0.47) KDM4EPRMT5WDR77SMN1; SMN2THRB
SCHEMBL964076 0.82 TSHR (0.43) GPR119IDO1SMN1; SMN2ALDH1A1MAPT
SCHEMBL8444736 0.80 KDM4E (0.59) GPR119KDM4EPKMSMN1; SMN2GAA
SCHEMBL16380488 0.80 TACR1 (0.44) GPR119JAK2JAK1KDM4EPKM
SCHEMBL1279865 0.80 TACR1 (0.44) GPR119JAK2JAK1KDM4EPKM
SCHEMBL1279861 0.80 TACR1 (0.44) GPR119JAK2JAK1KDM4EPKM
SCHEMBL585825 0.79 GPR119 (0.45) GPR119IDO1PRMT5WDR77SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
EP-2627630-B1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE BIOPHARMA R & D IP LLC (US) 2014-12-31 EP disclosed
EP-2627630-B1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE BIOPHARMA R & D IP LLC (US) 2014-12-31 EP disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-8729119-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2014-05-20 US disclosed
US-8729119-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2014-05-20 US disclosed
US-8729119-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2014-05-20 US disclosed
US-20130253013-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2013-09-26 US disclosed
US-20130253013-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2013-09-26 US disclosed
US-20130253013-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2013-09-26 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253013-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 GPR119 628/4885JAK2 898/4885JAK1 850/4885
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 GPR119 628/4885JAK2 898/4885JAK1 850/4885
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 GPR119 628/4885JAK2 898/4885JAK1 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.